Biological impact assessment of nanomaterial used in nanomedicine. Introduction to the NanoTEST project

Nanotoxicology

Volumn 9, Issue S1, 2015, Pages 5-12

  Juillerat Jeanneret, Lucienne ^a   Dusinska, Maria ^b   Fjellsbo, Lise Marie ^b   Collins, Andrew R ^c   Handy, Richard D ^d   Riediker, Michael ^e  

^a UNIVERSITY INSTITUTE OF PATHOLOGY   (Switzerland)

^b NORWEGIAN INSTITUTE FOR AIR RESEARCH   (Norway)

^c UNIVERSITY OF OSLO   (Norway)

^d UNIVERSITY OF PLYMOUTH   (United Kingdom)

^e Institute for Work and Health   (Switzerland)

Author keywords

Biocompatibility; Nanoparticles; Risk assessment; Therapeutic nanomaterials

Indexed keywords

CAMPTOTHECIN; CARBOPLATIN; CISPLATIN; DOXORUBICIN; DRUG CARRIER; FLUOROURACIL; METHOTREXATE; NANOMATERIAL; NANOPARTICLE; PEGADEMASE; TAMOXIFEN;

ARTICLE; BIOAVAILABILITY; BIOCOMPATIBILITY; BIODEGRADATION; CELL FUNCTION; CHEMICAL COMPOSITION; CLINICAL TRIAL (TOPIC); DIAGNOSTIC IMAGING; DISPERSION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; EXCRETION; HEALTH IMPACT ASSESSMENT; HUMAN; IN VITRO STUDY; INFORMATION; MODEL; NANOMEDICINE; NANOTECHNOLOGY; NEOPLASM; NONHUMAN; OBSERVATION; PHENOTYPE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; RISK ASSESSMENT; SCREENING; TISSUES; TOXICITY; TOXICITY TESTING; MATERIALS TESTING; PROCEDURES;

ANIMALIA;

HUMANS; MATERIALS TESTING; NANOMEDICINE; NANOPARTICLES; NANOSTRUCTURES;

EID: 84929661596     PISSN: 17435390     EISSN: 17435404     Source Type: Journal    
DOI: 10.3109/17435390.2013.826743     Document Type: Article

References (63)

1. Baun A, Hansen SF. 2008. Environmental challenges for nanomedicine. Nanomedicine 3:605-608.
2. Borak B, Biernat P, Prescha A, Baszczuk A, Pluta J. 2012. In vivo study on the biodistribution of silica particles in the bodies of rats. Adv Clin Exp Med 21:13-18.
3. Borm PJ, Müller-Schulte D. 2006. Nanoparticles in drug delivery and environmental exposure: same size, same risks? Nanomed 1:235-224.
4. Bosi S, Feruglio L, Da Ros T, Spalluto G, Gregoretti B, Terdoslavich M, et al. 2004. Hemolytic effects of water-soluble fullerene derivatives. J Med Chem 47:6711-6715.
5. Boulaiz H, Alvarez PJ, Ramirez A, Marchal JA, Prados J, Rodŕiguez-Serrano F, et al. 2011. Nanomedicine: application areas and development prospects. Int J Mol Sci 12:3303-3321.
6. Bouwmeester H, Lynch I, Marvin HJ, Dawson KA, Berges M, Braguer D, et al. 2011. Minimal analytical characterization of engineered nanomaterials needed for hazard assessment in biological matrices. Nanotoxicology 1-1:11.
7. Brook RD, Rajagopalan S, Pope CA, Brook JR, Bhatnagar A, Diez-Roux AV, et al. 2010. Particulate matter air pollution and cardiovascular disease: an update to the scientific statement from the American Heart Association. Circulation 121:2331-2378.
8. Casals E, Pfaller T, Duschl A, Oostingh GJ, Puntes V. 2010. Time evolution of the nanoparticle protein Corona. ACS Nano 4:3623-3632.
9. DIRECTIVE 2001/20/EC of the European Parliament and of the Council of 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the Member States relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use. http://www.eortc.be/services/doc/clinical-eu-directive-04-april-01.pdf. Accessed on 04 February 2013.
10. DIRECTIVE 2004/27/EC of the European Parliament and of the Council of 31 March 2004 amending Directive 2001/83/EC on the Community code relating to medicinal products for human use. http://eurlex. europa.eu/LexUriServ/LexUriServ.do?uriOJ:L:2004:136:0034:0057: EN:PDF. Accessed on 04 February 2013.
11. Dobrovolskaia MA, McNeil SE. 2007. Immunological properties of engineered nanomaterials. Nat Nanotechnol 2:469-478.
12. Dusinska M, Fjellsbø LM, Magdolenova Z, Ravnum S, Rinna A, Runden-Pran E. 2011. Chapter 11: safety of nanomaterial in nanomedicine. In: Hunter RJ, Preedy VR, editors. Nanomedicine in health and disease. New Hampshire: CRC Press. pp 203-226.
13. Dusinska M, Magdolenova Z, Fjellsbø LM. 2013. Toxicological aspects for nanomaterial in humans. Chapter 1: nanotechnology for nucleic acid delivery. In: Oupicky D, Ogris M, editors. Methods in molecular biology. Vol. 948. New York: Humana Press. pp 1-12.
14. Dusinska M, Rundén-Pran E, Carreira SC, Saunders M. 2012. In vitro and in vivo toxicity test methods. Chapter 4: critical evaluation of toxicity tests. In: Fadeel B, Pietroiusti A, Shvedova A, editors. Adverse effects of engineered nanomaterials: exposure, toxicology and impact on human health. Elsevier, NY, USA. pp 63-84.
15. Dusinska M; the NanoTEST Consortium. 2009. Testing strategies for the safety of nanoparticles used in medical application. Nanomedicine 4: 605-607.
16. Duvall MN. editor. 2012. FDA regulation on nanotechnology. pp 1-135. http://www.shb.com/newsevents/2012/FDARegulationofNanotechno logy.pdf.
17. Dziendzikowska K, Gromadzka-Ostrowska J, Lankoff A, Oczkowski M, Krawczyńska A, Chwastowska J, et al. 2012. Time-dependent biodistribution and excretion of silver nanoparticles in male Wistar rats. J Appl Toxicol 32:920-928European Comission. Nanomaterials http://ec.europa.eu/environment/chemicals/nanotech/index.htm.
18. EFSA. 2009. Scientific opinion of the scientific committee on a request from the European commission on the potential risks arising from nanoscience and nanotechnologies on food and feed safety. EFSA J 958:1-39.
19. EFSA. 2011. Guidance on the risk assessment of the application of nanoscience and nanotechnologies in the food and feed chain. EFSA J 9:2140; 1-36.
20. EU directive 1223/2009 REGULATION (EC) No 1223/2009 of the European Parliament and of the Council of 30 November 2009 on cosmetic products Official Journal of the European Union L 342/75. http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uriOJ:L:2009:342:0059:0209:en:PDF.
21. FDA. 2010. Center for drug evaluation and research, office of pharmaceutical science, reporting format for nanotechnology-related information in cmc review, manual of policies and procedures 5015.9. http://www.fda.gov/downloads/AboutFDA/CentersOffices/CDER/Manualof PoliciesProcedures/UCM214304.pdf.
22. FDA. 2012. Code of Federal Regulations, Title 21, volume 5, Food and Drugs, Chapter 1 Food and Drug Administration Department of Health and Human Services Subchapter D - Drugs for human use (part 312) investigational new drug applications. [21CFR312 revised as of April 1, 2012]. http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFR Search.cfm?CFRPart312&showFR1.
23. Godin B, Driessen WH, Proneth B, Lee SY, Srinivasan S, Rumbaut R, et al. 2010. An integrated approach for the rational design of nanovectors for biomedicalimaging and therapy. Adv Genet 69:31-64.
24. Godin B, Tasciotti E, Liu X, Serda RE, Ferrari M. 2011. Multistage nanovectors: from concept to novel imaging contrast agents and therapeutics. Acc Chem Res 44:979-989.
25. Handy RD, Henry TB, Scown TM, Johnstone BD, Tyler CR. 2008b. Manufactured nanoparticles: their uptake and effects on fish - a mechanistic analysis. Ecotoxicology 17:396-409.
26. Handy RD, von der Kammer F, Lead JR, Hassellöv M, Owen R, Crane M. 2008a. The ecotoxicology and chemistry of manufactured nanoparti-cles. Ecotoxicology 17:287-314.
27. Hirn S, Semmler-Behnke M, Schleh C, Wenk A, Lipka J, Schäffler M, et al. 2011. Particle size-dependent and surface charge-dependent biodistribution of gold nanoparticles after intravenous administration. Eur J Pharm Biopharm 77:407-416.
28. ISO. 2006a. 14040: Environmental management - Life cycle assessment - Principles and framework.
29. ISO. 2006b. 14044: Environmental management - Life cycle assessment - Requirement and guidelines.
30. Juillerat-Jeanneret L. 2006. Critical analysis of cancer therapy using nanomaterials. In: Kumar CSSR, editor. Nanomaterials for cancer therapy and diagnosis. Vol. 6. Serie: nanotechnologies for life sciences. WILEY-VCH Verlag; Weinheim, Germany. pp 199-232.
31. Klaine SJ, Koelmans AA, Horne N, Carley S, Handy RD, Kapustka L, et al. 2012. Paradigms to assess the environmental impact of manufactured nanomaterials. Environ Toxico Chem 31:3-14.
32. Kreyling WG, Semmler-Behnke M, Chaudhry Q. 2010. A complementary definition of nanomaterial. Nano Today 5:165-168.
33. Lai D. 2012. Toward toxicity testing of nanomaterials in the 21st century: a paradigm for moving forward. WIREs Nanomed Nanobiotechnol 4: 1-15.
34. Lammers T, Aime S, Hennink WE, Storm G, Kiessling F. 2011. Theranostic nanomedicine. Acc Chem Res 44:1029-1038.
35. Lundqvist M, Stigler J, Cedervall T, Berggård T, Flanagan MB, Lynch I, et al. 2011. The evolution of the protein Corona around nanoparticles: a test study. ACS Nano 5:7503-7509.
36. Malkiewicz K, Hansson SO, Ruden C. 2009. Assessment factors for extrapolation from short-time to chronic exposure-are the REACH guidelines adequate? Toxicol Lett 190:16-22.
37. Milani S, Baldelli Bombelli F, Pitek AS, Dawson KA, Rädler J. 2012. Reversible versus irreversible binding of transferrin to polystyrene nanoparticles: soft and hard Corona. ACS Nano 6:2532-2541.
38. Mills NL, Amin N, Robinson SD, Anand A, Davies J, Patel D, et al. 2006. Do inhaled carbon nanoparticles translocate directly into the circulation in humans? Am J Respir Crit Care Med 173:426-431.
39. Monopoli MP, Walczyk D, Campbell A, Elia G, Lynch I, Bombelli FB, et al. 2011. Physical-chemical aspects of protein corona: relevance to in vitro and in vivo biological impacts of nanoparticles. J Am Chem Soc 133:2525-2534.
40. Naahidi S, Jafari M, Edalat F, Raymond K, Khademhosseini A, Chen P. 2013. Biocompatibility of engineered nanoparticles for drug delivery. J Control Release 166:182-194.
41. Nel A, Xia T, Meng H, Wang X, Lin S, Ji Z, et al. 2013. Nanomaterial toxicity testing in the 21st century: use of a predictive toxicological approach and high-throughput screening. Acc Chem Res (Mar 19) 46(3):607-21.
42. Oberdörster G, Sharp Z, Atudorei V, Elder A, Gelein R, Kreyling W, et al. 2004. Translocation of inhaled ultrafine particles to the brain. Inhal Toxicol 16:437-445.
43. OECD. 2013. Directorate for Science, Technology and Industry Committee for Scientific and Technological Policy Working Party on Nanotechnology, Regulatory Frameworks for Nanotechnology in Foods and Medical products. Summary results of a survey activity. DSTI/STP/NANO(2012)22/FINAL. 1-51. http://search.oecd.org/officialdo-cuments/publicdisplaydocumentpdf/?coteDSTI/STP/NANO(2012)22/FINAL&docLanguageEn.
44. Pablico-Lansigan MH, Situ SF, Samia AC. 2013. Magnetic particle imaging: advancements and perspectives for real-time in vivo monitoring and image-guided therapy. Nanoscale 5:4040-4055.
45. Patel VR, Agrawal YK. 2011. Nanosuspension: An approach to enhance solubility of drugs. J Adv Pharm Technol Res 2:81-87.
46. Pautler M, Brenner S. 2010. Nanomedicine: promises and challenges for the future of public health. Int J Nanomed 5:803-809.
47. REGULATION (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency. http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uriOJ:L:2004:136:0001:0033:en:PDF. Accessed 04 Ferburay 2013.
48. SCCS. 2012. Guidance on the safety assessment of nanomaterials in cosmetics (SCCS/1484/12). http://ec.europa.eu/health/scientificcom-mittees/consumersafety/docs/sccss005.pdf.
49. SCENIHR (Scientific Committee on Emerging and Newly Identified Health Risks). 2009. Risk assessment of products of nanotechnologies. 1-71. http://ec.europa.eu/health/archive/phrisk/committees/04sce-nihr/docs/scenihro023.pdf.
50. SCENIHR (Scientific Committee on Emerging and Newly Identified Health Risks). 2012. Request for a scientific opinion: Health effects of nanomaterials used in Medical Devices. http://ec.europa.eu/health/scientificcommittees/emerging/docs/scenihrq032.pdf.
51. SCENIHR (Scientific Committee on Emerging and Newly-Identified Health Risks). 2007. The appropriateness of the risk assessment methodology in accordance with the Technical Guidance Documents for new and existing substances for assessing the risks of nanomaterials http://ec.europa.eu/health/archive/phrisk/committees/04scenihr/docs/scenihro003b.pdf.
52. SCHER (Scientific Committees on Health and Environmental Risks). 2013. Emerging and Newly Identified Health Risks SCENIHR, Consumer Safety SCCS. Addressing the New Challenges for Risk Assessment. 1-157. http://ec.europa.eu/health/scientificcommittees/consumersafety/docs/sccso131.pdf.
53. Schrand AM, Dai L, Schlager JJ, Hussain SM. 2012. Toxicity testing of nanomaterials. Adv Experim Med Biol 745:58-75.
54. Schütz CA, Juillerat-Jeanneret L, Mueller H, Lynch I, Riediker MNanoImpactNet Consortium. 2013a. Therapeutic nanoparticles in clinics and under clinical evaluation. Nanomedicine (Lond) 8:449-67.
55. Schütz CA, Juillerat-Jeanneret L, Soltmann C, Müller H. 2013b. Toxicity data of therapeutic nanoparticles in patent documents. World Patent Information 35:110-14.
56. Sebekova K, Dusinska M, Simon Klenovics K, Kollarova R, Boor P, Kebis A, et al. 2014. Comprehensive assessment of nephrotoxicity of intravenously administered sodium-oleate-coated ultrasmall superpar-amagnetic iron oxide (USPIO) and titanium dioxide (TiO2) nanopar-ticles in rats. Nanotoxicology 8:142-157.
57. Setyan A, Sauvain JJ, Guillemin M, Riediker M, Demirdjian B, Rossi MJ. 2010. Probing functional groups at the gas-aerosol interface using heterogeneous titration reactions: a tool for predicting aerosol health effects? ChemPhysChem 11:3823-3835.
58. Som C, Berges M, Chaudhry Q, Dusinska M, Fernandes TF, Olsen SI, et al. 2010. The importance of life cycle concepts for the development of safe nanoproducts. Toxicology 269:160-169.
59. Stone V, Nowack B, Baun A, van den Brink N, von der Kammer F, Dusinska M, et al. 2010. Nanomaterials for environmental studies: classification, reference material issues, and strategies for physico-chemical characterization. Sci Total Environ 408:1745-1754.
60. Teow Y, Asharani PV, Hande MP, Valiyaveettil S. 2011. Health impact and safety of engineered nanomaterials. Chem Commun 47: 7025-7038.
61. Tosi G, Vergoni AV, Ruozi B, Bondioli L, Badiali L, Rivasi F, et al. 2010. Sialic acid and glycopeptides conjugated PLGA nanoparticles for central nervous system targeting: In vivo pharmacological evidence and biodistribution. J Control Release 145:49-57.
62. Volkovova K, Handy RD, Ulicna O, Kucharská J, Staruchova M, Kebis A, et al. 2015. Health effects of selected nanoparticlesin vivo: Liver function and hepatotoxicity following intravenous injection of TiO2 or iron nanoparticles in rodents. Nanotoxicology 9(S1):95-105.
63. Warheit DB, Borm PJA, Hennes C, Jurgen L. 2007. Testing strageties to establish the safety of nanomaterials: conclusions of an ECETOC workshop. Inhal Toxicol 19:631-643.